Drew Pardoll
Overview
Explore the profile of Drew Pardoll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
8726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jackson C, Cherry C, Bom S, Dykema A, Wang R, Thompson E, et al.
Science
. 2025 Jan;
387(6731):eabm5214.
PMID: 39818911
The role of glioma-associated myeloid cells in tumor growth and immune evasion remains poorly understood. We performed single-cell RNA sequencing of immune and tumor cells from 33 gliomas, identifying two...
2.
Yu H, Nishio H, Barbi J, Mitchell-Flack M, Vignali P, Zheng Y, et al.
Elife
. 2024 Nov;
13.
PMID: 39565188
The adaptive T cell response is accompanied by continuous rewiring of the T cell's electric and metabolic state. Ion channels and nutrient transporters integrate bioelectric and biochemical signals from the...
3.
Alkhatib H, Maroun C, Guller M, Cooper D, Wu E, Eisele D, et al.
Otolaryngol Head Neck Surg
. 2023 Dec;
170(3):828-836.
PMID: 38123496
Objective: This study examines the association between patient-reported allergy history and immune checkpoint inhibition (ICI) response in patients with recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC). Study...
4.
Guller M, Cooper D, Alkhatib H, Suru A, Blancaflor A, Maroun C, et al.
Head Neck
. 2023 Sep;
45(11):2789-2797.
PMID: 37682116
Objectives: To explore the impact of pre-existing comorbidities on immunotherapy response, overall and progression-free survival, and immune-related adverse events (irAEs) of patients with advanced head and neck cancer (HNC) treated...
5.
Jackson C, Cherry C, Bom S, Dykema A, Thompson E, Zheng M, et al.
bioRxiv
. 2023 Apr;
PMID: 37034584
One-sentence Summary: Aggressive glioblastoma harbors two unique myeloid populations capable of promoting stem-like properties of tumor cells and suppressing T cell function in the tumor microenvironment.
6.
Harbison R, Pandey R, Considine M, Leone R, Murray-Stewart T, Erbe R, et al.
Cancer Res Commun
. 2022 Sep;
2(7):639-652.
PMID: 36052016
Metabolic features of the tumor microenvironment (TME) antagonize anti-tumor immunity. We hypothesized that T cell infiltrated tumors with a known antigen should exhibit superior clinical outcomes, though some fare worse...
7.
Schad S, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, et al.
J Exp Med
. 2022 May;
219(6).
PMID: 35604411
Transcription factors ThPOK and Runx3 regulate the differentiation of "helper" CD4+ and "cytotoxic" CD8+ T cell lineages respectively, inducing single positive (SP) T cells that enter the periphery with the...
8.
Alkhatib H, Maroun C, Amin N, Zhu G, Guller M, Herberg M, et al.
JAMA Otolaryngol Head Neck Surg
. 2022 Apr;
148(6):540-546.
PMID: 35482301
Importance: Tumor histological factors that predict immunotherapy response in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) are not well defined. Objective: To investigate the association...
9.
Guller M, Herberg M, Amin N, Alkhatib H, Maroun C, Wu E, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830929
The association between pretreatment nutritional status and immunotherapy response in patients with advanced head and neck cancer is unclear. We retrospectively analyzed a cohort of 99 patients who underwent treatment...
10.
Amin N, Maroun C, El Asmar M, Alkhatib H, Guller M, Herberg M, et al.
Head Neck
. 2021 Nov;
44(2):562-571.
PMID: 34825751
Given the recent successes of anti-PD-1 immunotherapy, many clinical trials have sought to assess the safety and efficacy of this treatment modality in the neoadjuvant setting. This systematic review provides...